JP6936814B2 - Ｎｉｋ阻害剤としてのシアノインドリン誘導体 - Google Patents
Ｎｉｋ阻害剤としてのシアノインドリン誘導体 Download PDFInfo
- Publication number
- JP6936814B2 JP6936814B2 JP2018562323A JP2018562323A JP6936814B2 JP 6936814 B2 JP6936814 B2 JP 6936814B2 JP 2018562323 A JP2018562323 A JP 2018562323A JP 2018562323 A JP2018562323 A JP 2018562323A JP 6936814 B2 JP6936814 B2 JP 6936814B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- het
- ring
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *C1(*)c(cc(cc2C#N)-c3c(*)cnc(N*)n3)c2NC1 Chemical compound *C1(*)c(cc(cc2C#N)-c3c(*)cnc(N*)n3)c2NC1 0.000 description 4
- SLTBEMKENUGZDJ-UHFFFAOYSA-N CC(C)(C)OC(N(CC(C)(C)c1cc(B2OC(C)(C)C(C)(C)O2)c2)c1c2C#N)=O Chemical compound CC(C)(C)OC(N(CC(C)(C)c1cc(B2OC(C)(C)C(C)(C)O2)c2)c1c2C#N)=O SLTBEMKENUGZDJ-UHFFFAOYSA-N 0.000 description 1
- LMZFKPMVPYWCDJ-UHFFFAOYSA-N CC(C)(C)OC(N(CC1(C)CC(F)F)c(c(C#N)c2)c1cc2-c1ccnc(Nc2cc(CN(C)CC3)c3nc2OC)n1)=O Chemical compound CC(C)(C)OC(N(CC1(C)CC(F)F)c(c(C#N)c2)c1cc2-c1ccnc(Nc2cc(CN(C)CC3)c3nc2OC)n1)=O LMZFKPMVPYWCDJ-UHFFFAOYSA-N 0.000 description 1
- PCXOEUNTZHTWGD-UHFFFAOYSA-N CC(C)(C)OC(N(Cc1ccc2)Cc1c2Nc1nccc(-c(cc2C(C)(C)C3)cc(C#N)c2N3C(OC(C)(C)C)=O)n1)=O Chemical compound CC(C)(C)OC(N(Cc1ccc2)Cc1c2Nc1nccc(-c(cc2C(C)(C)C3)cc(C#N)c2N3C(OC(C)(C)C)=O)n1)=O PCXOEUNTZHTWGD-UHFFFAOYSA-N 0.000 description 1
- SDQWKGCTMUGQEG-UHFFFAOYSA-N CC(C)(C[n](cc1)c2c1c(C)cc(Cl)c2)O Chemical compound CC(C)(C[n](cc1)c2c1c(C)cc(Cl)c2)O SDQWKGCTMUGQEG-UHFFFAOYSA-N 0.000 description 1
- NRYYEDMGETYEKN-UHFFFAOYSA-N CC(C)c1c(CN(C)CC2)[n]2nc1N Chemical compound CC(C)c1c(CN(C)CC2)[n]2nc1N NRYYEDMGETYEKN-UHFFFAOYSA-N 0.000 description 1
- CTILFWYUBMVGBP-VOVKCACBSA-N CC(CC[n]1nc2)Oc1c2Nc1nc(-c2cc(C#N)c3NC[C@](C)(CO)c3c2)ccn1 Chemical compound CC(CC[n]1nc2)Oc1c2Nc1nc(-c2cc(C#N)c3NC[C@](C)(CO)c3c2)ccn1 CTILFWYUBMVGBP-VOVKCACBSA-N 0.000 description 1
- TZXZORTZRONZMX-UHFFFAOYSA-N CC(c1c2)OCC[n]1nc2Nc1nccc(-c(cc2C#N)cc(C(C)(C)C3)c2N3C(OC(C)(C)C)=O)n1 Chemical compound CC(c1c2)OCC[n]1nc2Nc1nccc(-c(cc2C#N)cc(C(C)(C)C3)c2N3C(OC(C)(C)C)=O)n1 TZXZORTZRONZMX-UHFFFAOYSA-N 0.000 description 1
- CHZIPZYXTBZPHD-UHFFFAOYSA-N CC(c1c2)OCC[n]1nc2Nc1nccc(-c2cc(C#N)c3NCC(C)(C)c3c2)n1 Chemical compound CC(c1c2)OCC[n]1nc2Nc1nccc(-c2cc(C#N)c3NCC(C)(C)c3c2)n1 CHZIPZYXTBZPHD-UHFFFAOYSA-N 0.000 description 1
- DAFMPCUOKTXUTE-UHFFFAOYSA-N CC1(CC(F)F)c2cc(-c3ccnc(Nc4cc(CN(C)CC5)c5nc4OC)n3)cc(C#N)c2NC1 Chemical compound CC1(CC(F)F)c2cc(-c3ccnc(Nc4cc(CN(C)CC5)c5nc4OC)n3)cc(C#N)c2NC1 DAFMPCUOKTXUTE-UHFFFAOYSA-N 0.000 description 1
- QDARUFJCBOVFBR-UHFFFAOYSA-N CC1(CO)c2cc(-c3ccnc(Nc4cc(Cl)cc5c4cc[n]5CC(NC)=O)n3)cc(C#N)c2NC1 Chemical compound CC1(CO)c2cc(-c3ccnc(Nc4cc(Cl)cc5c4cc[n]5CC(NC)=O)n3)cc(C#N)c2NC1 QDARUFJCBOVFBR-UHFFFAOYSA-N 0.000 description 1
- IUUPHZMDODZZRY-UHFFFAOYSA-N CN(C)C(C[n](ccc1c2)c1nc(OC)c2N)=O Chemical compound CN(C)C(C[n](ccc1c2)c1nc(OC)c2N)=O IUUPHZMDODZZRY-UHFFFAOYSA-N 0.000 description 1
- AVFZOVWCLRSYKC-UHFFFAOYSA-N CN1CCCC1 Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 1
- PAMIQIKDUOTOBW-UHFFFAOYSA-N CN1CCCCC1 Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N CN1CCNCC1 Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- SJRJJKPEHAURKC-UHFFFAOYSA-N CN1CCOCC1 Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 1
- XTGCJRCYGWLUHJ-UHFFFAOYSA-N CN1CCOCCC1 Chemical compound CN1CCOCCC1 XTGCJRCYGWLUHJ-UHFFFAOYSA-N 0.000 description 1
- JDVWLHHVKYUADU-WAYWQWQTSA-N COC(/C=C1\NCCC1)=O Chemical compound COC(/C=C1\NCCC1)=O JDVWLHHVKYUADU-WAYWQWQTSA-N 0.000 description 1
- QIQMNEHRKKJYAH-UHFFFAOYSA-N COc(nc(CCOC1)c1c1)c1Nc1nc(Cl)ncn1 Chemical compound COc(nc(CCOC1)c1c1)c1Nc1nc(Cl)ncn1 QIQMNEHRKKJYAH-UHFFFAOYSA-N 0.000 description 1
- GVJDHBMLVFYJRC-UHFFFAOYSA-N Cc(cc(cc[n]1CC(N(C)C)=O)c1n1)c1OC Chemical compound Cc(cc(cc[n]1CC(N(C)C)=O)c1n1)c1OC GVJDHBMLVFYJRC-UHFFFAOYSA-N 0.000 description 1
- DLOMQOWIMZASSJ-UHFFFAOYSA-N Cc(cc1Cl)c(C)c2c1[nH]cc2 Chemical compound Cc(cc1Cl)c(C)c2c1[nH]cc2 DLOMQOWIMZASSJ-UHFFFAOYSA-N 0.000 description 1
- XHOALJZWZGCQJS-UHFFFAOYSA-N Cc1c(cc[nH]2)c2cc(Cl)c1 Chemical compound Cc1c(cc[nH]2)c2cc(Cl)c1 XHOALJZWZGCQJS-UHFFFAOYSA-N 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N Cc1c(cc[nH]2)c2ccc1 Chemical compound Cc1c(cc[nH]2)c2ccc1 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- UGPQJGVRYCXMLN-UHFFFAOYSA-N Cc1c(cc[n]2CCN3CCOCC3)c2cc(Cl)c1 Chemical compound Cc1c(cc[n]2CCN3CCOCC3)c2cc(Cl)c1 UGPQJGVRYCXMLN-UHFFFAOYSA-N 0.000 description 1
- DIQYHDORGXRAFP-UHFFFAOYSA-N Cc1cc(COCC2)c2nc1 Chemical compound Cc1cc(COCC2)c2nc1 DIQYHDORGXRAFP-UHFFFAOYSA-N 0.000 description 1
- RDHALFWHSFHPPL-UHFFFAOYSA-N Cc1cc(Cl)cc2c1cc[n]2CC(NC)=O Chemical compound Cc1cc(Cl)cc2c1cc[n]2CC(NC)=O RDHALFWHSFHPPL-UHFFFAOYSA-N 0.000 description 1
- HWUXPVLTCKJQAO-UHFFFAOYSA-N Cc1cc(Cl)cc2c1cc[n]2CCC(NC)=O Chemical compound Cc1cc(Cl)cc2c1cc[n]2CCC(NC)=O HWUXPVLTCKJQAO-UHFFFAOYSA-N 0.000 description 1
- LNMUVPQSLQKKLG-UHFFFAOYSA-N Cc1cc(Cl)cc2c1cc[n]2CCCN1CCOCC1 Chemical compound Cc1cc(Cl)cc2c1cc[n]2CCCN1CCOCC1 LNMUVPQSLQKKLG-UHFFFAOYSA-N 0.000 description 1
- DPGFQCTTYIJAJX-UHFFFAOYSA-N Cc1cc(Cl)cc2c1cc[n]2CCCOC Chemical compound Cc1cc(Cl)cc2c1cc[n]2CCCOC DPGFQCTTYIJAJX-UHFFFAOYSA-N 0.000 description 1
- FBQSMVHWHHQNAA-UHFFFAOYSA-N Cc1cc(F)cc2c1cc[nH]2 Chemical compound Cc1cc(F)cc2c1cc[nH]2 FBQSMVHWHHQNAA-UHFFFAOYSA-N 0.000 description 1
- YPKBCLZFIYBSHK-UHFFFAOYSA-N Cc1ccc2[nH]ccc2c1 Chemical compound Cc1ccc2[nH]ccc2c1 YPKBCLZFIYBSHK-UHFFFAOYSA-N 0.000 description 1
- YZKSKVCMWQXBIT-UHFFFAOYSA-N Cc1cnc(CCN(C)C2)c2c1 Chemical compound Cc1cnc(CCN(C)C2)c2c1 YZKSKVCMWQXBIT-UHFFFAOYSA-N 0.000 description 1
- DJCJHFFRHKGOCQ-UHFFFAOYSA-N Cc1cnc2[nH]ccc2c1 Chemical compound Cc1cnc2[nH]ccc2c1 DJCJHFFRHKGOCQ-UHFFFAOYSA-N 0.000 description 1
- FVEIJXQIQLWVDC-UHFFFAOYSA-N NC1=CC(COCC2)=C2N(CCC2CC2)C1=O Chemical compound NC1=CC(COCC2)=C2N(CCC2CC2)C1=O FVEIJXQIQLWVDC-UHFFFAOYSA-N 0.000 description 1
- VBZYQNOXOUKFFN-UHFFFAOYSA-N Nc1cc(Cl)cc2c1cc[n]2CCCN1CCOCC1 Chemical compound Nc1cc(Cl)cc2c1cc[n]2CCCN1CCOCC1 VBZYQNOXOUKFFN-UHFFFAOYSA-N 0.000 description 1
- PDGLKOOWTGQNSS-UHFFFAOYSA-N [O-][N+](c1n[n](CCOC2)c2c1)=O Chemical compound [O-][N+](c1n[n](CCOC2)c2c1)=O PDGLKOOWTGQNSS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16177131.6 | 2016-06-30 | ||
| EP16177147 | 2016-06-30 | ||
| EP16177131 | 2016-06-30 | ||
| EP16177142 | 2016-06-30 | ||
| EP16177142.3 | 2016-06-30 | ||
| EP16177147.2 | 2016-06-30 | ||
| PCT/EP2017/066125 WO2018002219A1 (en) | 2016-06-30 | 2017-06-29 | Cyanoindoline derivatives as nik inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019524646A JP2019524646A (ja) | 2019-09-05 |
| JP2019524646A5 JP2019524646A5 (enExample) | 2020-08-06 |
| JP6936814B2 true JP6936814B2 (ja) | 2021-09-22 |
Family
ID=59227756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018562323A Active JP6936814B2 (ja) | 2016-06-30 | 2017-06-29 | Ｎｉｋ阻害剤としてのシアノインドリン誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20190119299A1 (enExample) |
| EP (1) | EP3478673B1 (enExample) |
| JP (1) | JP6936814B2 (enExample) |
| KR (1) | KR102587619B1 (enExample) |
| CN (1) | CN109689645B (enExample) |
| AU (1) | AU2017289317B2 (enExample) |
| ES (1) | ES2837157T3 (enExample) |
| WO (1) | WO2018002219A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017125534A1 (en) | 2016-01-22 | 2017-07-27 | Janssen Pharmaceutica Nv | New 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors |
| JP6910359B2 (ja) | 2016-01-22 | 2021-07-28 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｎｉｋ阻害剤としての新たな置換されたシアノインドリン誘導体 |
| JP6936815B2 (ja) | 2016-06-30 | 2021-09-22 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｎｉｋ阻害剤としてのヘテロ芳香族誘導体 |
| AU2017289317B2 (en) | 2016-06-30 | 2021-04-01 | Janssen Pharmaceutica Nv | Cyanoindoline derivatives as NIK inhibitors |
| FI3976597T3 (fi) | 2019-05-31 | 2024-09-25 | Janssen Pharmaceutica Nv | Nf-kb:tä indusoivan kinaasin pienimolekyylisiä estäjiä |
| EP3994133A4 (en) * | 2019-07-04 | 2023-11-22 | Qilu Regor Therapeutics Inc. | Hpk1 inhibitors and uses thereof |
| TW202304906A (zh) * | 2021-04-08 | 2023-02-01 | 大陸商杭州阿諾生物醫藥科技有限公司 | 高活性hpk1激酶抑制劑 |
| CN114380806B (zh) * | 2022-03-24 | 2022-06-10 | 中国药科大学 | 2-氨基-4-吲哚基嘧啶类化合物及其制备方法与应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60039059D1 (de) * | 1999-10-07 | 2008-07-10 | Amgen Inc | Triazin-kinase-hemmer |
| MXPA02007957A (es) | 2000-02-17 | 2002-11-29 | Amgen Inc | Inhibidores de cinasas. |
| ES2254385T3 (es) | 2000-02-29 | 2006-06-16 | Millennium Pharmaceuticals, Inc. | Benzamidas e inhibidores relacionados del factor xa. |
| ES2292753T4 (es) * | 2001-03-29 | 2009-02-16 | Vertex Pharmaceuticals Incorporated | Inhibidores de quinasas n-terminales c-jun (jnk) y otras proteina quinasas. |
| JP2005500294A (ja) | 2001-06-19 | 2005-01-06 | ブリストル−マイヤーズ スクイブ カンパニー | ホスホジエステラーゼ７に対するピリミジン阻害剤 |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| MX2007004488A (es) * | 2004-10-13 | 2007-09-11 | Wyeth Corp | Analogos de anilino-pirimidina n-bencenosulfonilo sustituidos. |
| US20110086834A1 (en) * | 2008-06-26 | 2011-04-14 | Amgen Inc. | Alkynyl alcohols as kinase inhibitors |
| CA2986640C (en) | 2008-06-27 | 2019-03-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| US20110183975A1 (en) * | 2008-10-07 | 2011-07-28 | Yasuhiro Goto | Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity |
| CN108752280A (zh) | 2009-08-17 | 2018-11-06 | 纪念斯隆-凯特琳癌症中心 | 热休克蛋白结合化合物、组合物以及其制备和使用方法 |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| ES2823350T3 (es) | 2010-07-29 | 2021-05-06 | Rigel Pharmaceuticals Inc | Compuestos heterocíclicos que activan AMPK y métodos de uso de los mismos |
| WO2012142329A1 (en) | 2011-04-12 | 2012-10-18 | Myrexis, Inc. | Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors |
| TWI663166B (zh) * | 2013-04-24 | 2019-06-21 | 健生藥品公司 | 新化合物 |
| WO2015030847A1 (en) | 2013-08-30 | 2015-03-05 | Ptc Therapeutics, Inc. | Substituted pyrimidine bmi-1 inhibitors |
| TWI627173B (zh) * | 2013-09-26 | 2018-06-21 | 比利時商健生藥品公司 | 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物 |
| TWI704146B (zh) * | 2013-09-26 | 2020-09-11 | 比利時商健生藥品公司 | 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物 |
| SG11201608242XA (en) | 2014-04-04 | 2016-10-28 | Syros Pharmaceuticals Inc | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| WO2015176135A1 (en) | 2014-05-22 | 2015-11-26 | The University Of Sydney | Omega-3 analogues |
| WO2016022645A1 (en) | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
| WO2016049211A1 (en) * | 2014-09-26 | 2016-03-31 | Gilead Sciences, Inc. | Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds |
| CN106928216A (zh) * | 2015-12-31 | 2017-07-07 | 中国科学院上海药物研究所 | 具有erk激酶抑制活性的化合物、其制备方法和用途 |
| JP6910359B2 (ja) | 2016-01-22 | 2021-07-28 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｎｉｋ阻害剤としての新たな置換されたシアノインドリン誘導体 |
| WO2017125534A1 (en) * | 2016-01-22 | 2017-07-27 | Janssen Pharmaceutica Nv | New 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors |
| SI3429591T1 (sl) | 2016-03-16 | 2023-07-31 | Kura Oncology, Inc. | Substituirani tieno(2,3-d)pirimidinski derivati kot inhibitorji menin-MLL in postopki uporabe |
| AU2017289317B2 (en) | 2016-06-30 | 2021-04-01 | Janssen Pharmaceutica Nv | Cyanoindoline derivatives as NIK inhibitors |
| JP6936815B2 (ja) | 2016-06-30 | 2021-09-22 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｎｉｋ阻害剤としてのヘテロ芳香族誘導体 |
-
2017
- 2017-06-29 AU AU2017289317A patent/AU2017289317B2/en active Active
- 2017-06-29 KR KR1020197002912A patent/KR102587619B1/ko active Active
- 2017-06-29 JP JP2018562323A patent/JP6936814B2/ja active Active
- 2017-06-29 ES ES17733469T patent/ES2837157T3/es active Active
- 2017-06-29 WO PCT/EP2017/066125 patent/WO2018002219A1/en not_active Ceased
- 2017-06-29 CN CN201780053613.3A patent/CN109689645B/zh active Active
- 2017-06-29 EP EP17733469.5A patent/EP3478673B1/en active Active
- 2017-06-29 US US16/309,080 patent/US20190119299A1/en not_active Abandoned
-
2020
- 2020-02-06 US US16/783,810 patent/US11186589B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3478673A1 (en) | 2019-05-08 |
| CN109689645B (zh) | 2022-06-03 |
| KR102587619B1 (ko) | 2023-10-11 |
| EP3478673B1 (en) | 2020-09-16 |
| AU2017289317A1 (en) | 2019-01-17 |
| WO2018002219A1 (en) | 2018-01-04 |
| US11186589B2 (en) | 2021-11-30 |
| AU2017289317B2 (en) | 2021-04-01 |
| ES2837157T3 (es) | 2021-06-29 |
| JP2019524646A (ja) | 2019-09-05 |
| CA3027418A1 (en) | 2018-01-04 |
| US20210032267A1 (en) | 2021-02-04 |
| US20190119299A1 (en) | 2019-04-25 |
| KR20190025949A (ko) | 2019-03-12 |
| CN109689645A (zh) | 2019-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6936814B2 (ja) | Ｎｉｋ阻害剤としてのシアノインドリン誘導体 | |
| JP6936815B2 (ja) | Ｎｉｋ阻害剤としてのヘテロ芳香族誘導体 | |
| JP6910359B2 (ja) | Ｎｉｋ阻害剤としての新たな置換されたシアノインドリン誘導体 | |
| JP6916796B2 (ja) | Ｎｉｋ阻害剤としての新たな６員のヘテロ芳香族置換シアノインドリン誘導体 | |
| US10323045B2 (en) | Thienopyrimidine derivatives as NIK inhibitors | |
| WO2015044269A1 (en) | NEW 3-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS | |
| KR102662373B1 (ko) | Nik 억제제로서의 신규 치환 아자인돌린 유도체 | |
| RU2780577C2 (ru) | Новые замещенные производные азаиндолина в качестве ингибиторов nik | |
| CA3027418C (en) | Cyanoindoline derivatives as nik inhibitors | |
| HK1261385B (en) | New substituted cyanoindoline derivatives as nik inhibitors | |
| HK1261385A1 (en) | New substituted cyanoindoline derivatives as nik inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190109 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20200601 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200625 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200625 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20200625 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210415 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210427 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210701 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210810 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210827 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6936814 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |